文献速递免疫规划卫生政策与健康促进

孟加拉国轮状病毒疫苗接种的影响与成本效果

Impact and cost-effectiveness of rotavirus vaccination in Bangladesh.
PubMed 文献 · Vaccine · 2017-06-13

该分析使用TRIVAC模型评估孟加拉国2017年引入两剂轮状病毒疫苗与不接种相比的影响和成本效果,采用三个死亡场景、社会视角、连续十个出生队列和3%贴现率。有Gavi补贴时每避免一个DALY成本为58至142美元,无补贴且疫苗价格2.19美元/剂时为615至1514美元。作者认为常规轮状病毒疫苗接种很可能具有成本效果。

要点

  • 有Gavi补贴时每避免一个DALY成本为58至142美元。
  • 无Gavi补贴且疫苗价格2.19美元/剂时每避免一个DALY成本为615至1514美元。

核心结论

  • 在几乎所有考虑的场景中,每避免一个DALY的贴现成本低于人均GDP,表明常规轮状病毒疫苗接种规划很可能具有成本效果。
  • 即使在没有Gavi补贴的低死亡场景下,轮状病毒疫苗接种仍具有成本效果。
  • 这些估计未包括疫苗接种的群体免疫效益,因此代表孟加拉国轮状病毒疫苗接种成本效果的保守估计。

研究设计与样本

  • 使用泛美卫生组织TRIVAC模型(版本2.0)评估2017年在全国范围引入两剂轮状病毒疫苗接种与不接种相比的影响和成本效果。
  • 评估了三个死亡场景(低、高和中点),从社会视角检查连续十个出生队列的效益和成本,贴现率为3%。
  • 模型输入为当地获取的数据,并辅以国际验证的估计值。

主要发现

  • 有Gavi补贴时,每避免一个DALY的成本/DALY比率为58至142美元。
  • 无Gavi补贴且疫苗价格为2.19美元/剂时,每避免一个DALY的成本/DALY比率为615至1514美元。

关键数值与推荐

  • 有Gavi补贴时,每避免一个DALY的成本/DALY比率为58至142美元。
  • 无Gavi补贴且疫苗价格为2.19美元/剂时,每避免一个DALY的成本/DALY比率为615至1514美元。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些估计未包括疫苗接种的群体免疫效益,因此代表孟加拉国轮状病毒疫苗接种成本效果的保守估计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diarrheal disease is a leading cause of child mortality globally, and rotavirus is responsible for more than a third of those deaths. Despite substantial decreases, the number of rotavirus deaths in children under five was 215,000 per year in 2013. Of these deaths, approximately 41% occurred in Asia and 3% of those in Bangladesh. While Bangladesh has yet to introduce rotavirus vaccination, the country applied for Gavi support and plans to introduce it in 2018. This analysis evaluates the impact and cost-effectiveness of rotavirus vaccination in Bangladesh and provides estimates of the costs of the vaccination program to help inform decision-makers and international partners. METHODS: This analysis used Pan American Health Organization's TRIVAC model (version 2.0) to examine nationwide introduction of two-dose rotavirus vaccination in 2017, compared to no vaccination. Three mortality scenarios (low, high, and midpoint) were assessed. Benefits and costs were examined from the societal perspective over ten successive birth cohorts with a 3% discount rate. Model inputs were locally acquired and complemented by internationally validated estimates. RESULTS: Over ten years, rotavirus vaccination would prevent 4000 deaths, nearly 500,000 hospitalizations and 3 million outpatient visits in the base scenario. With a Gavi subsidy, cost/disability adjusted life year (DALY) ratios ranged from $58/DALY to $142/DALY averted. Without a Gavi subsidy and a vaccine price of $2.19 per dose, cost/DALY ratios ranged from $615/DALY to $1514/DALY averted. CONCLUSION: The discounted cost per DALY averted was less than the GDP per capita for nearly all scenarios considered, indicating that a routine rotavirus vaccination program is highly likely to be cost-effective. Even in a low mortality setting with no Gavi subsidy, rotavirus vaccination would be cost-effective. These estimates exclude the herd immunity benefits of vaccination, so represent a conservative estimate of the cost-effectiveness of rotavirus vaccination in Bangladesh.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pecenka C, Parashar U, Tate JE, et al. Impact and cost-effectiveness of rotavirus vaccination in Bangladesh. Vaccine. 2017. PMID: 28623028. doi:10.1016/j.vaccine.2017.05.087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。